Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 38
B
Biographies of the Organizing
Committee Members
Douglas A. Lauffenburger (Co-chair) is a professor of biological engineering,
chemical engineering, and biology, co-director of the Biological Engineering Di-
vision, and director of the biotechnology process engineering center at the Mas-
sachusetts Institute of Technology. He received a B.S. from the University of
Illinois and a Ph.D. in chemical engineering from the University of Minnesota.
His research combines molecular cell biology with engineering approaches to
improve design of cell-based technologies and molecular therapeutics. Dr.
Lauffenburger's awards include the A. P. Colburn, W. H. Walker, and Food Phar-
maceutical and Bioengineering Division awards from the American Institute of
Chemical Engineers; the C. W. McGraw award from the American Society for
Engineering Education; and the Amgen Award in Biochemical Engineering from
the Engineering Foundation. He is also a member of the National Academy of
Engineering, American Academy of Arts and Sciences, past president of the Bio-
medical Engineering Society, and a member of the NIH General Medical Sci-
ences Advisory Council.
Christopher T. Walsh (Co-chair) is currently the Hamilton Kuhn Professor of
Biological Chemistry and Molecular Pharmacology at Harvard Medical School.
His research efforts have been directed to enzymatic catalysis, including analysis
of the chemical basis of molecular transformations and the study of enzyme in-
hibitors. This has led to study of the mechanism of agents in various areas of
molecular pharmacology, including immunosuppressive agents and antibacterial
drugs. Dr. Walsh earned his A.B. from Harvard University and his Ph.D. from
Rockefeller University. Dr. Walsh is a member of both the National Academy of
Sciences and the Institute of Medicine. He spent the first part of his career in the
38
OCR for page 39
APPENDIX B
39
chemistry department at MIT. He sits on the board of directors and advisory
board of many corporations and has won such awards as the Alfred P. Sloan
Foundation Fellowship (1975), Eli Lilly Award in Biochemistry (1979), the
Arthur C. Cope Scholar Award of the American Chemical Society, and the ACS's
Repligen Award. Dr. Walsh has also been on the Editorial Board of the Journal of
the American Chemical Society and is a member of the NIH General Medical
Sciences Advisory Council.
Paul S. Anderson is the vice-president for drug discovery at Bristol-Myers
Squibb Company. He previously held comparable positions at DuPont Pharma-
ceutical Company and DuPont-Merck Pharmaceutical Company. Before joining
DuPont-Merck he was the vice-president for chemistry at Merck Sharp & Dohme
Research Laboratories, where he served in various roles from senior research
chemist through executive director of the medicinal chemistry department. Dr.
Anderson received a B.S. from University of Vermont and a Ph.D. in chemistry
from University of New Hampshire. He performed postgraduate studies as a Na-
tional Institutes of Health postdoctoral fellow in chemistry at Cornell University.
He is a foyer president of the American Chemical Society.
Ellen Leahy is a senior scientist in medicinal chemistry at Celera in South San
Francisco, California. She earned both her B.S. and Ph.D. from the University of
South Florida and was a postdoctoral scholar at the University of Pennsylvania in
the laboratory of Ralph Hirschmann. Dr. Leahy has worked in the San Francisco
Bay area biotechnology industry focusing on combinatorial chemistry as well as
traditional medicinal chemistry programs. During the course of her career she has
held positions at Affymax and Versicor and then at Axys Pharmaceuticals, which
became part of Celera in 2001. She recently received the Outstanding Chemistry
Alumni Award at the University of South Florida.
Michael A. Marletta is currently a professor of chemistry and biochemistry and
molecular biology at the University of California, Berkeley, and a professor of
cellular and molecular pharmacology at the University of California, San Fran-
cisco. He was previously on the faculty at the University of Michigan and the
Massachusetts Institute of Technology. His research focuses on the interface of
chemistry and biology, probing biological catalysis and other protein structure
and function questions. Novel functions and mechanisms are explored for appli-
cation of those properties to drug design. Dr. Marietta has a number of awards
that include a MacArthur Foundation Fellowship, the State of Michigan Scientist
of the Year, and the Distinguished Faculty Achievement Award from the Univer-
sity of Michigan. He is a member of the Institute of Medicine and a fellow of the
American Academy of Arts and Sciences. He earned his A.B. at State University
College in Fredonia, New York, and his Ph.D. at the University of California, San
. _ .
. ~ranclsco.
OCR for page 40
40
APPENDIX B
C. Dale Poulter is the John A. Widtsoe Distinguished Professor in the Depart-
ment of Chemistry at the University of Utah. He earned his B.S. from Louisiana
State University and his Ph.D. from the University of California, Berkeley. He
was a National Institutes of Health postdoctoral fellow with Saul Winstein at the
University of California, Los Angeles. Dr. Poulter's research combines synthetic
and mechanistic organic chemistry with biochemistry and molecular biology to
study the chemistry of enzyme catalysis. This work has focused on enzymes in
the isoprenoid biosynthetic pathway, including those in sterol biosynthesis and
protein prenylation. He has been awarded an Alfred P. Sloan Fellowship, the
American Chemical Society Ernest Guenther Award, an ACS Arthur C. Cope
Scholar Award, and the ACS Repligen Award. He is a fellow of the American
Association for the Advancement of Science. Dr. Poulter has served on a number
of ACS committees and editorial advisory boards and is the editor in chief of the
Journal of Organic Chemistry.
Dagmar Ringe is a professor of biochemistry and chemistry at Brandeis Univer-
sity. Her research group studies the relationship of protein three-dimensional
structure to chemical function, using a combination of design of transition-state
analog inhibitors, site-directed mutagenesis, genetics, and X-ray crystallography.
Dr. Ringe received her Ph.D. from Boston University.
Representative terms from entire chapter:
medicinal chemistry
